lifestyle.thedishh.com

Author: Castle Biosciences, Inc.

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

March 9, 2026
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

March 4, 2026
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

March 3, 2026
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

February 27, 2026
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

February 27, 2026
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

February 19, 2026
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

February 7, 2026